Table 3.

Clinical and laboratory characteristics of CRS and neurotoxicity in SC IL-15 with haplo-NK-cell infusion

Patient	No. of IL-15 doses	CRS				Neurotoxicity				Ferritin, ng/mL	CRP, mg/L	IL-6 , pg/mL	Steroids	Tocilizumab	Disease response
		Onset (day)	Grade	Symptoms	Response	Onset (day)	Grade	Symptoms	Response
1	10	17	2	Fever, rash	Yes	44	3	Confusion	Yes	5 944	37	1 240	Yes	Yes	CRi
2	10	21	3	Hypotension	Yes	—	—	—	—	16 108	380	32 275	Yes	Yes	PD
3	8	11	2	Hypoxia, rash	Yes	11	2	Confusion	Yes	18 761	280	191	No	No	CRi
4	1	2	4	Fever	No	2	4	Confusion, dysarthria, status epilepticus	Yes	16 848	170	226	Yes	No	PD
5	9	8	1	Fever, rash	Yes	—	—	—	—	—	—	—	No	No	PD
6	6	7	1	Fever, hypotension	Yes	—	—	—	—	9 252	200	159	Yes	No	PD
7	7	8	4	Fever, rash, hypotension	Yes	22	4	Confusion, dysarthria, status epilepticus	Yes	133 439	150	125	Yes	Yes	PD
8	5	9	2	Fever, hypotension	Yes	—	—	—	—	50 408	160	248	Yes	No	CRi
9	10	7	4	Hypoxia	No	7	5	Confusion, hemiparesis, intracranial hemorrhage	No	13 711	420	243	Yes	Yes	NE